Oral transmucosal fentanyl citrate for the treatment of breakthrough pain: Results of a non-interventional study (NIS);Oral-transmukosales fentanylcitrat zur therapie von durchbruchschmerzen: Ergebnisse einer nichtinterventionellen studie (NIS)

Schmerz

Volumn 21, Issue 6, 2007, Pages 545-552

  Zarth, R ^a   Ehmer, M ^b   Sittig, H B ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Praxis für Schmerztherapie und Palliativmedizin   (Germany)

^c Spezielle Schmerztherapie/Palliativmedizin   (Germany)

Author keywords

Breakthrough pain; Cancer related pain; Observational study; Oral transmucosal fentanyl citrate

Indexed keywords

FENTANYL CITRATE;

ADULT; AGED; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN THRESHOLD; PROSPECTIVE STUDY; RATING SCALE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 36649018162     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-007-0590-z     Document Type: Article

References (25)

1. Aronoff GM, Brennan MJ, Pritchard DD, Ginsberg B (2005) Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 6: 305-314
2. Arzneimittelkommission der deutschen Ärzteschaft (2007) Empfehlungen zur Therapie von Tumorschmerzen. Arznei Praxis 34: 1-32
3. Christie JM, Simmonds M, Patt R et al. (1998) Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16: 3238-3245
4. Coluzzi PH (1998) Cancer pain management: newer perspectives on opioids and episodic pain. Am J Hosp Palliat Care 15: 13-22
5. Coluzzi PH, Schwartzberg L, Conroy JD et al. (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91: 123-130
6. Farrar JT, Cleary J, Rauck R et al. (1998) Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90: 611-616
7. Hanks GW, Conno F, Cherny N et al. (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587-593
8. Hanks GW, Nugent M, Higgs CM, Busch MA (2004) Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med 18: 698-704
9. Hanks G, Portenoy R, MacDonald N, Forbes K (1998) Difficult pain problems. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 454-477
10. Lichtor JL, Sevarino FB, Joshi GP et al. (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 89: 732-738
11. McMenamin E, Farrar JT (2002) OTFC: a novel agent for breakthrough pain related to cancers. Expert Rev Neurother 2: 625-629
12. Mercadante S, Radbruch L, Caraceni A et al. (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94: 832-839
13. Payne R, Coluzzi P, Hart L et al. (2001) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 22: 575-583
14. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273-281
15. Portenoy RK, Hagen NA (1991) Breakthrough pain: definition and manifestations. Prim Care Cancer: 27-33
16. Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129-134
17. Portenoy RK, Payne R, Coluzzi P et al (1999) Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303-312
18. Radbruch L, Nauck F (2002) Morphin und andere Opioide in der Tumorschmerztherapie. Die Empfehlungen der EAPC. Schmerz 16: 186-193
19. Rees E (2002) The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs 8: 304-308
20. Streisand JB, Busch MA, Egan TD et al (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88: 305-309
21. Streisand JB, Varvel JR, Stanski DR et al (1991) Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75: 223-229
22. Svendsen KB, Andersen S, Arnason S et al (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9: 195-206
23. Taylor DR, Webster LR, Chun SY et al (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 8: 281-288
24. Vainio A, Auvinen A (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12: 3-10
25. Zeppetella G, O'Doherty CA, Collins S (2001) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20: 87-92